2017-08-23
INTERIM REPORT FOR KANCERA AB (publ) JANUARI 1ST – JUNE 30TH 2017
This is a translation from the original report published in Swedish August 22nd 2017.
Read More
2017-02-21
INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December 31st 2016
THE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...
Read More
2016-11-18
Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016
The period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating income for the period amounted to SEK -15.8m (SEK...
Read More
2016-08-19
Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016
As a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts of the Annual Accounts Act. The consolidated financial statements...
Read More
2016-05-03
Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016
The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...
Read More
2016-02-19
Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015
The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted SEK 8.3m (SEK 4.1m). Following EU’s approval of Kancera’s...
Read More
2015-11-20
Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.
The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...
Read More
2015-08-21
Interim Report for Kancera AB (publ) Q2 2015, January 1 – June 30, 2015
The period January to June 2014 and the second quarter 2015 in brief R&D expenses for the period amounted to SEK 8.8m (SEK 6.9m) of which the second quarter constituted SEK 4.6m (SEK 3.4m). Operating income for the period...
Read More
2015-05-22
Interim Report for Kancera AB (publ) Q1 2015 January 1 – March 31, 2015
In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read More
2015-02-20
Full Year Report for Kancera AB (publ) Q4 2014 January 1 – December 31, 2014
In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read More